[Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].
Spiekermann
K
K
Klinische Kooperationsgruppe "Leukämie" und Labor für Leukämiediagnostik, Medizinische Klinik III, Klinikum Grosshadern der Ludwig-Maximilians-Universität München und GSF-Hämatologikum, München. k.spiekermann@gmx.de
Hiddemann
W
W
Schnittger
S
S
D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism / Q000502:physiology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic; D006410:Hematopoiesis / Q000235:genetics / Q000502:physiology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D009154:Mutation; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism / Q000502:physiology; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism / Q000502:physiology; D051941:fms-Like Tyrosine Kinase 3
D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; D011518:Proto-Oncogene Proteins; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3